Skip to Content

Arixtra 7.5 mg / dose (fondaparinux) Disease Interactions

There are 6 disease interactions with Arixtra 7.5 mg / dose (fondaparinux):

Major

Factor Xa Inhibitors (Includes Arixtra 7.5 mg/dose) ↔ Bleeding

Severe Potential Hazard, Moderate plausibility

Applies to: Bleeding

The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding. Its use increases the risk of bleeding and can cause serious or fatal bleeding. Caution is recommended when prescribing these agents to patients at increased risk of bleeding. When using these agents, the risk of thrombotic events should be weighed against the risk of bleeding.

Major

Factor Xa Inhibitors (Includes Arixtra 7.5 mg/dose) ↔ Hepatic Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

In general, the manufacturer recommends avoiding the use of factor Xa inhibitors in patients with moderate and severe hepatic impairment or with any hepatic disease associated with coagulopathy as drug exposure and bleeding risk may be increased.

Major

Factor Xa Inhibitors (Includes Arixtra 7.5 mg/dose) ↔ Renal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Some factor Xa inhibitors such as rivaroxaban and fondaparinux should be avoided in patients with CrCl <30 mL/min. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Treatment should be discontinued in patients who develop acute renal failure while on treatment with these drugs.

Major

Factor Xa Inhibitors (Includes Arixtra 7.5 mg/dose) ↔ Valvular Heart Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Prosthetic Heart Valves

The use of factor Xa inhibitors is not recommended in patients with prosthetic heart valves as no studies have been conducted for safety and efficacy.

Major

Fondaparinux (Includes Arixtra 7.5 mg/dose) ↔ Bacterial Endocarditis

Severe Potential Hazard, Moderate plausibility

Applies to: Infectious Endocarditis

The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.

Moderate

Fondaparinux (Includes Arixtra 7.5 mg/dose) ↔ Thrombocytopenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Thrombocytopenia

Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.

Arixtra 7.5 mg / dose (fondaparinux) drug Interactions

There are 224 drug interactions with Arixtra 7.5 mg / dose (fondaparinux)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide